METTL1 and hepatocellular carcinoma: Recent studies suggest that blocking the axis of METTL1-TGF-β2-PMN-MDSC may be a therapeutic strategy to restore anti-tumor immunity and reduce HCC recurrence after radio frequency ablation (RFA) therapy (Li R. et al., 2023; Zeng et al., 2023).